# Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

Study · id `cardio:ct-nct02874794` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02874794](<https://clinicaltrials.gov/study/NCT02874794>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02874794

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 465 participants.

## Technical summary

Registry record NCT02874794. Randomized; triple masking; primary purpose treatment. Start 2016-08-17 (actual); primary completion 2018-12-13 (actual). Results posted on 2020-03-19.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 465 participants (enrolled count; ClinicalTrials.gov record NCT02874794, source copy `cardio:ctgov-nct02874794-2021-01-05`, retrieved 2026-10-26)
- Started: 2016-08-17 (actual) (ClinicalTrials.gov record NCT02874794, source copy `cardio:ctgov-nct02874794-2021-01-05`, retrieved 2026-10-26)
- Primary completion: 2018-12-13 (actual) (ClinicalTrials.gov record NCT02874794, source copy `cardio:ctgov-nct02874794-2021-01-05`, retrieved 2026-10-26)
- Completion: 2019-01-26 (actual) (ClinicalTrials.gov record NCT02874794, source copy `cardio:ctgov-nct02874794-2021-01-05`, retrieved 2026-10-26)
- Results first posted: 2020-03-19 (ClinicalTrials.gov record NCT02874794, source copy `cardio:ctgov-nct02874794-2021-01-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02874794, source copy `cardio:ctgov-nct02874794-2021-01-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02874794-2021-01-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
- Acronym: EVALUATE-HF
- Condition: Heart Failure and Reduced Ejection Fraction
- Intervention (Drug): LCZ696 (sacubitril/valsartan)
- Intervention (Drug): Enalapril
- Intervention (Drug): Placebo of Enalapril
- Intervention (Drug): Placebo of LCZ696
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry intervention name matches this record: Enalapril (`cardio:enalapril`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex (`cardio:pubmed-33663237`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE-HF trial (`cardio:pubmed-35560696`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Changes in cardiac structure and function are associated with health-related quality of life in heart failure patients with reduced ejection fraction: Results from the EVALUATE-HF trial (`cardio:pubmed-40678912`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 00577625a1cac268f27f150208e5adfe0dd859ada9ac18e57e516d4b6f2811a3
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
